Gene therapy for the Wiskott-Aldrich syndrome

Current Opinion in Allergy and Clinical Immunology

Volumn 11, Issue 6, 2011, Pages 545-550

  Galy, Anne ^a   Thrasher, Adrian J ^b,c  

^a GÉNÉTHON   (France)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

gene therapy; hematopoietic stem cells; lentiviral vector; rare disease; Wiskott Aldrich syndrome

Indexed keywords

LENTIVIRUS VECTOR; RETROVIRUS VECTOR; WISKOTT ALDRICH SYNDROME PROTEIN;

ADAPTIVE IMMUNITY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CELLULAR IMMUNITY; DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION; GENE MUTATION; GENE THERAPY; GENOTYPE; HUMAN; LONG TERMINAL REPEAT; PRIORITY JOURNAL; REVIEW; WISKOTT ALDRICH SYNDROME;

CLINICAL TRIALS AS TOPIC; GENE THERAPY; GENETIC VECTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LENTIVIRUS; THROMBOCYTOPENIA; WISKOTT-ALDRICH SYNDROME; WISKOTT-ALDRICH SYNDROME PROTEIN;

EID: 80255138207     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e32834c230c     Document Type: Review

References (42)

1. Jin Y, Mazza C, Christie JR, et al. Mutations of the Wiskott-Aldrich syndrome protein (WASP): hotspots, effect on transcription, and translation and phenotype/genotype correlation. Blood 2004; 104:4010-4019.
2. Ochs HD. Mutations of the Wiskott-Aldrich syndrome protein affect protein expression and dictate the clinical phenotypes. Immunol Res 2009; 44:84-88.
3. Zhu Q, Zhang M, Blaese RM, et al. The Wiskott-Aldrich syndrome and X-linked congenital thrombocytopenia are caused by mutations of the same gene. Blood 1995; 86:3797-3804.
4. Imai K, Morio T, Zhu Y, et al. Clinical course of patients with WASP gene mutations. Blood 2004; 103:456-464.
5. Ochs HD, Filipovich AH, Veys P, et al. Wiskott-Aldrich syndrome: diagnosis, clinical and laboratory manifestations, and treatment. Biol Blood Marrow Transplant 2009; 15 (1 Suppl):84-90.
6. Thrasher AJ. New insights into the biology of Wiskott-Aldrich syndrome (WAS). Hematol Am Soc Hematol Educ Program 2009; 132-138.
7. Albert MH, Notarangelo LD, Ochs HD. Clinical spectrum, pathophysiology and treatment of the Wiskott-Aldrich syndrome. Curr Opin Hematol 2010. Epublication
8. Blundell MP, Worth A, Bouma G, Thrasher AJ. The Wiskott-Aldrich syndrome: the actin cytoskeleton and immune cell function. Dis Markers 2010; 29:157-175.
9. Thrasher AJ, Burns SO. WASP: a key immunological multitasker. Nat Rev Immunol 2010; 10:182-192.
10. Bouma G, Burns SO, Thrasher AJ. Wiskott-Aldrich syndrome: immunodeficiency resulting from defective cell migration and impaired immunostimulatory activation. Immunobiology 2009; 214:778-790.
11. Good RA. Bone marrow transplantation for immunodeficiency diseases. Am J Med Sci 1987; 294:68-74.
12. Pai SY, Notarangelo LD. Hematopoietic cell transplantation for Wiskott- Aldrich syndrome: advances in biology and future directions for treatment. Immunol Allergy Clin North Am 2010; 30:179-194.
13. Moratto D, Giliani S, Bonfim C, et al., Long-term outcome and lineage-specific chimerism in 194 Wiskott-Aldrich syndrome patients treated by hematopoietic cell transplantation between 1980-2009: an international collaborative study. Blood 2011. [Epub ahead of print]
14. Davis BR, Candotti F. Revertant somatic mosaicism in the Wiskott-Aldrich syndrome. Immunol Res 2009; 44:127-131.
15. Stewart DM, Candotti F, Nelson DL. The phenomenon of spontaneous genetic reversions in the Wiskott-Aldrich syndrome: a report of the workshop of the ESID Genetics Working Party at the XIIth Meeting of the European Society for Immunodeficiencies (ESID). Budapest, Hungary October 4-7, 2009. J Clin Immunol 2007; 27:634-639.
16. Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009; 360:447-458.
17. Gaspar HB, Cooray S, Gilmour KC, et al. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med 2011; 3:97ra79.
18. Hacein-Bey-Abina S, Hauer J, Lim A, et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2010; 363:355-364.
19. Gaspar HB, Cooray S, Gilmour KC, et al. Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med 2011; 3:97ra80.
20. Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008; 118:3132-3142.
21. Howe SJ, Mansour MR, Schwarzwaelder K, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008; 118:3143-3150.
22. Malech H, Maples PB, Whiting-Theobald N, et al. Prolonged production of nadph oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci U S A 1997; 94:12133-12138.
23. Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006; 12:401-409.
24. Kang HJ, Bartholomae CC, Paruzynski A, et al. Retroviral gene therapy for x-linked chronic granulomatous disease: results from phase I/II trial. Mol Ther. 2011. [Epub ahead of print]
25. Kang EM, Choi U, Theobald N, et al. Retrovirus gene therapy for x-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils. Blood 2010; 115:783-791.
26. Stein S, Ott MG, Schultze-Strasser S, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010; 16:198-204.
27. Boztug K, Schmidt M, Schwarzer A, et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med 2010; 363:1918-1927.
28. Baum C. Parachuting in the epigenome: the biology of gene vector insertion profiles in the context of clinical trials. EMBO Mol Med 2011; 3:75-77.
29. Ginn SL, Liao SH, Dane AP, et al. Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype correction independent of insertional mutagenesis and gammac overexpression. Mol Ther 2010; 18:965-976.
30. Paruzynski A, Arens A, Gabriel R, et al. Genome-wide high-throughput integrome analyses by nrLAM-PCR and next-generation sequencing. Nat Protoc 2010; 5:1379-1395.
31. Modlich U, Bohne J, Schmidt M, et al. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 2006; 108:2545-2553.
32. Dropulic B. Lentiviral vectors: their molecular design, safety, and use in laboratory and preclinical research. Hum Gene Ther 2011; 22:649-657.
33. Galy A, Roncarolo MG, Thrasher AJ. Development of lentiviral gene therapy for Wiskott-Aldrich syndrome. Expert Opin Biol Ther 2008; 8:181-190.
34. Zufferey R, Dull T, Mandel RJ, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72:9873-9880.
35. Zychlinski D, Schambach A, Modlich U, et al. Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol Ther 2008; 16:718-725.
36. Cattoglio C, Pellin D, Rizzi E, et al. High-definition mapping of retroviral integration sites identifies active regulatory elements in human multipotent hematopoietic progenitors. Blood 2010; 116:5507-5517.
37. Zanta-Boussif MA, Charrier S, Brice-Ouzet A, et al. Validation of a mutated PRE sequence allowing high and sustained transgene expression while abrogating WHV-X protein synthesis: application to the gene therapy of WAS. Gene Ther 2009; 16:605-619.
38. Merten OW, Charrier S, Laroudie N, et al. Large scale manufacture and characterisation of a lentiviral vector produced for clinical ex vivo gene therapy application. Hum Gene Ther 2011; 22:343-356.
39. Dupre L, Marangoni F, Scaramuzza S, et al. Efficacy of gene therapy for Wiskott-Aldrich syndrome using a WAS promoter/cDNA-containing lentiviral vector and nonlethal irradiation. Hum Gene Ther 2006; 17:303-313.
40. Marangoni F, Bosticardo M, Charrier S, et al. Evidence for long-term efficacy and safety of gene therapy for Wiskott-Aldrich syndrome in preclinical models. Mol Ther 2009; 17:1073-1082.
41. Mantovani J, Charrier S, Eckenberg R, et al. Diverse genomic integration of a lentiviral vector developed for the treatment of Wiskott-Aldrich syndrome. J Gene Med 2009; 11:645-654.
42. Modlich U, Navarro S, Zychlinski D, et al. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther 2009.